

Present and Future Collaborative Drug Discovery Informatics Innovations

BARRY A. BUNIN

Collaborative Drug Discovery, USA.

Abstract

Collaborative Drug Discovery (CDD) provides a whole solution for today's biological and chemical data needs, differentiated by ease-of-use and superior collaborative capabilities. CDD Vault® software includes Activity & Registration, Visualization, Inventory, and ELN capabilities. Researchers can archive, mine, and securely collaborate within CDD Vault. Collaborative hypothesis generation and evaluation allow multiple perspectives for multi-parameter optimization.

CDD's Research Informatics Group invents bleeding edge technologies. For example, the recently developed BioHarmony data store provides real-time semantic drug reports. In addition, BioHarmony Annotator allows more sophisticated assay registration and management. Case studies will be shared from industry (Jubilant Biosys), government (NIH Neuroscience Blueprint), non-profit (Gates Foundation), and numerous leading academic collaborations. Patients (n=15) who did not require pre-repair intervention, did not have post-repair complication and did not require intervention in follow up had better QoL (PCS 63 vs 51, MCS 82 vs 56, p<0.03) than those (n=32) who required pre-repair intervention, had post-repair complication, required intervention in follow up; their mental QoI (MCS 82 vs 98 p=0.08) was similar to those who underwent uncomplicated LC (n=50).

Received: July 05, 2022; **Accepted:** July 12, 2022; **Published:** July 20, 2022

Biography

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen \$50 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a

selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen's \$10.4 Billion acquisition of Onyx Pharmaceuticals.